Setting the Stage for MDD Recovery: Strategies for the Busy Primary Care Provider
February 4, 2021
February 4 2022
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Medical Education Resources and CMEology.
This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.
- Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)™
- Nurses — 1.5 Nursing Contact Hours
- Family Practice — 1.5 AAFP Prescribed credits
All other health care professionals completing this course will be issued a statement of participation.
The audience for this educational initiative is primary care clinicians who care for patients with major depressive disorder.
In the United States, most adults with major depressive disorder (MDD) are treated by primary care providers (PCPs). Therefore, it is essential that PCPs are adept at using patient-centered care to set the stage for MDD recovery. In particular, PCPs must be prepared to detect and respond to two of the most common threats to recovery: residual MDD symptoms and intolerable side effects of antidepressants. In these articles, 2 expert faculty members discuss how busy PCPs can optimize MDD care by implementing shared decision making; employing measurement-based care; identifying and managing MDD residual symptoms and antidepressant side effects; and switching patients to new antidepressants when necessary. Two patient cases illustrate evidence-based approaches to common clinical scenarios.
Upon completion of this activity, participants should be better able to:
- Explain the practical benefits of incorporating shared decision-making and patient goals into MDD treatment plans
- Identify tools suited to measure MDD symptoms and patient wellness during a primary care office visit
- Demonstrate knowledge of evidence-based strategies for treating MDD residual symptoms
- Formulate an appropriate treatment plan for a patient experiencing a side effect related to their antidepressant
- Analyze whether and how to switch a patient’s MDD therapy
W. Clay Jackson, MD, DipTh
Clinical Assistant Professor
Family Medicine and Psychiatry
University of Tennessee College of Medicine
Michael E. Thase, MD
Professor of Psychiatry
Department of Psychiatry
Mood and Anxiety Disorders Treatment and Research Program
Perelman School of Medicine at the University of Pennsylvania
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians.
Medical Education Resources designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Family Practice Credit
The AAFP has reviewed Setting the Stage for MDD Recovery: Strategies for the Busy Primary Care Provider and deemed it acceptable for up to 1.50 Enduring Materials, Self-Study AAFP Prescribed credit. Term of Approval is from 01/01/2021 to 01/01/2022. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This CE activity provides 1.5 contact hours of continuing nursing education.
Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.
Disclosures of Conflicts of Interest
Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
W. Clay Jackson, MD, DipTh
- Consulting Fees: Abbvie, Inc/Allergan, Inc; Genentech, Inc; Otsuka Pharmaceutical Company, Ltd; and Sunovion Pharmaceuticals, Inc.
Michael E. Thase, MD
- Consulting Fees: Acadia, Inc; Akili, Inc; Alkermes PLC; Allergan, Inc (Forest, Naurex); Gerson Lehrman Group, Inc; H. Lundbeck; A/S; Jazz Pharmaceuticals; Johnson & Johnson (Janssen); Merck & Company, Inc.; Otsuka Pharmaceutical Company, Ltd; Pfizer, Inc.
- Grant Support: Acadia, Inc; Allergan, Inc (Forest, Naurex); Axsome Therapeutics Inc.; Intracellular, Inc; Johnson & Johnson (Janssen); Otsuka Pharmaceutical Company, Ltd; Patient-Centered Outcomes Research Institute (PCORI); Takeda
- Royalties: American Psychiatric Foundation; Guilford Publications; Herald House; W.W. Norton & Company, Inc.
- Spouse’s Employment: Peloton Advantage, which does business with most major pharmaceutical companies
CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.
Instructions for Participation and Credit
After reviewing the learning objectives and reading the supplement, please complete the Activity Evaluation/Credit Request form online at https://www.cmesurvey.site/MDDJFP. AMA PRA Category 1 Credit™, AAFP prescribed credits and ANCC contact hours are provided. This educational activity should take a maximum of 1.5 hours to complete.
There is no fee for this educational activity.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.